Chord Therapeutics is a clinical stage biopharmaceutical company focused on developing targeted therapies for rare diseases caused by genetic mutations. Their approach utilizes precision medicine to create effective treatments that address unmet medical needs in patient populations with limited therapeutic options.
Funding
$16M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many rare diseases are caused by specific genetic mutations, leaving patients with limited or no effective treatment options. Developing therapies for these conditions is challenging due to the small patient populations and the need for precise targeting of the underlying genetic defect.
Solution
Chord Therapeutics is a biopharmaceutical company dedicated to developing targeted therapies for rare diseases caused by genetic mutations. Their precision medicine approach aims to create effective treatments that address the root cause of these diseases, offering hope to patient populations with significant unmet medical needs. By focusing on the genetic basis of these conditions, Chord Therapeutics seeks to develop therapies that are more effective and have fewer side effects than traditional treatments.
Target Audience
The primary target audience includes patients suffering from rare diseases caused by genetic mutations, as well as their families and healthcare providers.
Features
- Focus on developing therapies for rare diseases with a genetic basis.
- Precision medicine approach to target specific genetic mutations.
- Development of therapies designed to address the underlying cause of the disease.
- Aims to provide more effective treatments with fewer side effects.